Public Health Groups Close Ranks Against Tobacco Industry

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 10
Volume 6
Issue 10

WASHINGTON-The Administration’s demand that Congress strengthen areas of the proposed tobacco agreement (see article above) won praise from a number of organizations that had criticized the initial settlement as too weak. “The opportunity to enact the right tobacco policy has never been greater,” said John R. Seffrin, PhD, chief executive officer of the American Cancer Society.

WASHINGTON—The Administration’s demand that Congress strengthen areas of the proposed tobacco agreement (see article above) won praise from a number of organizations that had criticized the initial settlement as too weak. “The opportunity to enact the right tobacco policy has never been greater,” said John R. Seffrin, PhD, chief executive officer of the American Cancer Society.

The ACS has joined forces with 10 other major national public health organizations to garner grassroots support to help move the proposal through Congress quickly before momentum fades.

ASCO’s Position

The American Society of Clinical Oncology (ASCO), in a statement issued a few days before the President’s address, also called for major changes to strengthen the proposed settlement.

Of special concern is the focus of the $25 billion research fund included in the tobacco settlement. The Society wants to see the fund sponsor a balanced portfolio of basic and clinical research on tobacco-related cancers and other diseases, and install a rigorous, science-based, peer-reviewed system for making grants.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
2 experts are featured in this series.
4 experts in this video
5 experts are featured in this series
5 experts are featured in this series
Osimertinib/chemotherapy and amivantamab/lazertinib have exhibited an efficacy advantage vs osimertinib in patients with EGFR-mutant NSCLC.
Related Content